干扰素信号随年龄增长而减弱并与三阴性乳腺癌免疫检查点阻断疗效相关
该研究在小鼠和患者层面探讨年龄对三阴性乳腺癌(TNBC)免疫检查点阻断(ICB)疗效的影响。老年荷瘤小鼠ICB疗效受限,老年小鼠和TNBC患者的肿瘤微环境均显示干扰素信号和抗原呈递下降;使用STING激动剂触发先天免疫 priming 可恢复老年小鼠对ICB的应答。数据提示年龄相关免疫功能障碍是小鼠ICB耐药机制,并建议评估IFN相关基因对接受ICB的TNBC患者可能有预后价值。
要点
- 老年荷瘤小鼠中免疫功能障碍增加限制了ICB疗效。
- 老年小鼠和TNBC患者肿瘤微环境均显示IFN信号和抗原呈递下降。
- STING激动剂触发先天免疫 priming 可恢复老年小鼠对ICB的应答。
核心结论
- 年龄相关免疫功能障碍是小鼠中ICB耐药的机制之一。
- 评估IFN相关基因对接受ICB治疗的TNBC患者可能具有预后价值。
研究设计与样本
- 研究在荷TNBC小鼠中比较年龄对ICB疗效的影响,并分析老年小鼠和TNBC患者的肿瘤微环境。
- 原文未报告样本量、研究类型等设计细节。
主要发现
- 老年荷瘤小鼠中免疫功能障碍增加,限制了ICB疗效。
- 老年小鼠和TNBC患者的肿瘤微环境均显示IFN信号和抗原呈递下降。
- 使用STING激动剂触发先天免疫 priming 可恢复老年小鼠对ICB的应答。
临床怎么用
- 作者认为评估肿瘤基因组数据中的IFN相关基因可能有助于识别需要联合IFN通路激活剂与ICB治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade (ICB) therapy, which targets T cell-inhibitory receptors, has revolutionized cancer treatment. Among the breast cancer subtypes, evaluation of ICB has been of greatest interest in triple-negative breast cancer (TNBC) due to its immunogenicity, as evidenced by the presence of tumor-infiltrating lymphocytes and elevated PD-L1 expression relative to other subtypes. TNBC incidence is equally distributed across the age spectrum, affecting 10% to 15% of women in all age groups. Here we report that increased immune dysfunction with age limits ICB efficacy in aged TNBC-bearing mice. The tumor microenvironment in both aged mice and patients with TNBC shows decreased IFN signaling and antigen presentation, suggesting failed innate immune activation with age. Triggering innate immune priming with a STING agonist restored response to ICB in aged mice. Our data implicate age-related immune dysfunction as a mechanism of ICB resistance in mice and suggest potential prognostic utility of assessing IFN-related genes in patients with TNBC receiving ICB therapy. SIGNIFICANCE: These data demonstrate for the first time that age determines the T cell-inflamed phenotype in TNBC and affects response to ICB in mice. Evaluating IFN-related genes from tumor genomic data may aid identification of patients for whom combination therapy including an IFN pathway activator with ICB may be required.This article is highlighted in the In This Issue feature, p. 1143.
引用
- Sceneay J, Goreczny GJ, Wilson K, et al. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discov. 2019. PMID: 31217296. doi:10.1158/2159-8290.CD-18-1454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。